title: Betaine and nonalcoholic steatohepatitis: back to the future?
abstract: Nonalcoholic steatohepatitis (NASH) is an important indication for liver transplantation in many Western countries. Obesity and insulin resistance are the two most common risk factors for NASH, which can lead to recurrent NASH after liver transplantation. There is currently no approved therapy for NASH, and treatment is directed at risk factor modification and lifestyle changes. Betaine has been used for NASH, with mixed results, and may show promise in conjunction with other agents in clinical trials.
authors: Sandeep
authors: S
authors: Mukherjee
mesh_terms: D000818:Animals; D001622:Betaine / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005234:Fatty Liver / Q000188:drug therapy* / Q000209:etiology / Q000601:surgery; D006801:Humans; D007333:Insulin Resistance / Q000502:physiology; D016031:Liver Transplantation; D065626:Non-alcoholic Fatty Liver Disease; D009765:Obesity / Q000150:complications; D012307:Risk Factors
chemical_list: D001622:Betaine